Skip to main content
Erschienen in: Critical Care 1/2020

Open Access 19.03.2020 | COVID-19 | Research Letter

Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan

verfasst von: Yu Shi, Xia Yu, Hong Zhao, Hao Wang, Ruihong Zhao, Jifang Sheng

Erschienen in: Critical Care | Ausgabe 1/2020

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
Yu Shi and Xia Yu contributed equally to this work.
A comment to this article is available online at https://​doi.​org/​10.​1186/​s13054-020-02903-9.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The recent outbreak of coronavirus disease 2019 (COVID-19), caused by a new zoonotic coronary virus, SARS-CoV-2 [1], is being a great threat to public health. Up to February 11, 2020, it is reported that over 70,000 persons have been infected with SARS-CoV-2 in China [2]. The COVID-19 caused by SARS-CoV-2 infection represents a spectrum of clinical severity [35]. Some patients are asymptomatic or have merely mild upper respiratory tract symptoms. However, SARS-CoV-2 causes pneumonia that can be severe and characterized by fever, cough, dyspnea, bilateral pulmonary infiltrates, and acute respiratory injury. It is estimated that approximately 20% of patients are developing severe respiratory illness, with the overall mortality around 2.3% [2]. Thereby, it is critical to identify individuals who confer intrinsic susceptibility to become severe or even critically ill upon infection, for the purposes of prevention and treatment, especially when there is no drug directly targeting at SARS-CoV-2 that has been proven to be clinically effective. In the study, we explored potential host risk factors associated with severe cases at admission in a retrospective cohort of 487 patients in Zhejiang Province of China and attempt to establish a score system to identify high-risk individuals. We reviewed medical records, laboratory findings, and pulmonary CT scan of each patient with COVID-19, provided by the local health authority and inputted into a pre-specified electronic data collection form. Clinical outcomes were followed up to February 17, 2020. The primary endpoint was occurrence of death and severe cases.
A total of 487 COVID-19 patients were included for analysis, with 49 (10.1%) severe cases at admission. As shown in Table 1, severe cases are elderly (56 (17) vs. 45 (19), P < 0.001), with more male (73.5% vs. 50.9%, P = 0.003). They have a higher incidence of hypertension (53.1% vs. 16.7%, P < 0.001), diabetes (14.3% vs. 5.0%, P = 0.009), cardiovascular diseases (8.2% vs. 1.6%, P = 0.003), and malignancy (4.1% vs. 0.7%, P = 0.025), and less exposure to epidemic area (49.0% vs. 65.1%, P = 0.027), but more infected family members (P = 0.031). On multivariate analysis, elder age (OR 1.06 [95% CI 1.03–1.08], P < 0.001), male (OR 3.68 [95% CI 1.75–7.75], P = 0.001), and presence of hypertension (OR 2.71 [95% CI 1.32–5.59], P = 0.007) are independently associated with severe disease at admission, irrespective of adjustment of time to admission.
Table 1
Demographic, epidermiological characteristics, and underlying comorbidities of patients with confirmed 2019-nCoV infection
Variables
Total (N = 487)
Mild (N = 438)
Severe (N = 49)
P value
Age (years)
46 (19)
45 (19)
56 (17)
< 0.001
Sex
 Male
259 (53.2%)
223 (50.9%)
36 (73.5%)
 
 Female
228 (46.8%)
215 (49.1%)
13 (26.5%)
0.003
Occupation
 Agricultural worker
140 (28.7%)
122 (27.9%)
18 (36.7%)
 
 Self-employed
219 (45.0%)
203 (46.3%)
16 (32.7%)
 
 Employee
82 (16.8%)
79 (18.0%)
3 (6.1%)
 
 Retired
38 (7.8%)
26 (5.9%)
12 (24.5%)
 
 Student
8 (1.6%)
8 (1.8%)
0 (0%)
< 0.001
Smoking history
 Yes
40 (8.2%)
34 (7.8%)
6 (12.2%)
 
 No
434 (89.1%)
391 (89.3%)
43 (87.8%)
 
 Unknown
13 (2.7%)
13 (2.7%)
0 (0%)
0.331
Comorbidities
 Hypertension
99 (20.3%)
73 (16.7%)
26 (53.1%)
< 0.001
 Diabetes
29 (6.0%)
22 (5.0%)
7 (14.3%)
0.009
 Cardiovascular disease
11 (2.3%)
7 (1.6%)
4 (8.2%)
0.003
 Malignancy
5 (1%)
3 (0.7%)
2 (4.1%)
0.025
 Chronic liver diseases
22 (4.5%)
20 (4.6%)
2 (4.1%)
0.877
 Chronic renal diseases
7 (1.4%)
5 (1.1%)
2 (4.1%)
0.101
 Others
32 (6.6%)
27 (6.1%)
5 (10.2%)
0.279
Exposure to confirmed cases
186 (38.2%)
173 (39.5%)
13 (26.5%)
0.077
Family cluster
 0
392 (80.5%)
352 (80.4%)
40 (81.6%)
 
 1
67 (13.8%)
63 (14.4%)
4 (8.2%)
 
 2
12 (2.5%)
12 (2.7%)
0 (0%)
 
 ≥ 3
16 (3.3%)
11 (2.5%)
5 (10.2%)
0.031
Recent travel or residence to/in epidemic area
309 (63.4%)
285 (65.1%)
24 (49.0%)
0.027
Time from onset of symptom to admission
2 (3)
2 (3)
3 (5)
0.10
Data are expressed as mean ± standard deviation (SD), median (interquartile range), or number (percent). Comparisons between mild and severe cases were performed by the Mann-Whitney U test or a chi-square test
Then, we defined a host risk score on the basis of the three risk factors, to assess the intrinsic host susceptibility to develop severe cases of COVID-19 (Fig. 1a). As shown in Fig. 1b, a step-wise increase in the incidence of severe COVID-19 at admission was observed with the increment of the host risk score (P < 0.001). The performance of the score was also validated in 66 patients who presented mild at admission and were under follow-up during hospital stay. Fifteen patients progressed to severe COVID-19 within a median follow-up time of 15 days. No death was reported by the end of follow-up. A similar trend to the above was confirmed when analyzing the correlation between host risk score and occurrence of severe COVID-19 (P = 0.014) (see Fig. 1c).
In summary, by identifying host risk factors associated with severe COVID-19, this study shed light on the underlying mechanisms of disease progression. In particular, the major finding that hypertension is a host risk factor for severe COVID-19 may underscore the involvement of renin-angiotensin system (RAS) in the pathogenesis of this disease. Additionally, the host risk score provides a useful tool to identify high-risk individuals, which is helpful for designing specific strategies for prevention and treatment of this disease. But further studies, particularly those enrolling Wuhan patients, are needed to validate the findings.

Acknowledgements

Not applicable.
The ethics committee of the First Affiliated Hospital of Zhejiang University reviewed and approved this study. Written consent was obtained from each patient or his/her authorized representatives following a full explanation of the study.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.CrossRef Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.CrossRef
2.
Zurück zum Zitat Novel Coronavirus Pneumonia Emergency Response Epidemiology T. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145–51. Novel Coronavirus Pneumonia Emergency Response Epidemiology T. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145–51.
3.
Zurück zum Zitat Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.CrossRef Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.CrossRef
4.
Zurück zum Zitat Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.CrossRef Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.CrossRef
5.
Zurück zum Zitat Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, Li S-B, Wang H-Y, Zhang S, Gao H-N, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.CrossRef Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, Li S-B, Wang H-Y, Zhang S, Gao H-N, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.CrossRef
Metadaten
Titel
Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan
verfasst von
Yu Shi
Xia Yu
Hong Zhao
Hao Wang
Ruihong Zhao
Jifang Sheng
Publikationsdatum
19.03.2020
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 1/2020
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-020-2833-7

Weitere Artikel der Ausgabe 1/2020

Critical Care 1/2020 Zur Ausgabe

Passend zum Thema

ANZEIGE

IPD-Fallzahlen & Pneumokokken-Impfung bei Kindern in Deutschland

Das Niveau der postpandemischen Fallzahlen für invasive Pneumokokken-Erkrankungen (IPD) ist aus Sicht des Referenz-Zentrums für Streptokokken in Aachen alarmierend [1]. Wie sich die monatlichen IPD-Fallzahlen bei Kindern und Jugendlichen von Juli 2015 bis März 2023 entwickelt haben, lesen Sie hier.

ANZEIGE

HPV-Impfung: Auch für junge Erwachsene sinnvoll und wichtig

Auch nach dem 18. Lebensjahr kann eine HPV-Impfung sinnvoll und wichtig sein. Viele gesetzliche Krankenkassen übernehmen die Kosten auch zu einem späteren Zeitpunkt noch.

ANZEIGE

Impfstoffe – Krankheiten vorbeugen, bevor sie entstehen

Seit mehr als 130 Jahren entwickelt und produziert MSD Impfstoffe für alle Altersgruppen. Hier finden Sie nützliche Informationen und Praxismaterialien rund um das Thema Impfen.

MSD Sharp & Dohme GmbH